Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Comparing extremes of the spectrum, multivariable analyses generally showed significantly higher risks for patients with high ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...

Find out how lipoprotein(a) screening identifies women at long term cardiovascular risk and supports earlier prevention ...

A new study published in the Journal of American Medical Association showed that among healthy women, very high lipoprotein ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Among women, very high levels of lipoprotein(a) are associated with an increased risk for future cardiovascular disea ...

In an observational registry study of Swedish outpatients with type 1 diabetes, those who had high plasma lipoprotein(a) [Lp (a)] levels — defined as >120 nmol/L or approximately 50 mg/dL — were more ...

Lilly's muvalaplin lowered lipoprotein (a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose PR Newswire INDIANAPOLIS, Nov. 18, 2024 ...